Apollo Global Management has agreed to acquire Covis Pharma, which markets several ciclesonide aerosol products: the Alvesco MDI and Omnaris and Zetonna nasal sprays. Terms of the deal were not disclosed. Covis is currently owned by Cerberus Capital Management, which founded the company in 2011. In 2017, Covis acquired the US rights to the three ciclesonide … [Read more...] about Apollo Global Management agrees to acquire Covis Pharma
Business
Boehringer Ingelheim’s reusable Respimat SMI wins 2020 Pharmapack eco-design award
Boehringer Ingelheim's reusable Respimat soft mist inhaler has won the 2020 Pharmapack Eco-Design Award, the company said. As many as six medication cartridges can be used with this version of the Respimat before the device must be replaced, significantly reducing the amount of plastic waste. According to the company, the reusable Respimat is expected to save 776 … [Read more...] about Boehringer Ingelheim’s reusable Respimat SMI wins 2020 Pharmapack eco-design award
Sandoz has discontinued its US generic Advair Diskus program
According to Novartis's 2019 annual report, Novartis subsidiary Sandoz has discontinued development of a generic version of the Advair Diskus fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD for the US market as of January 2020. In October 2016, Sandoz filed a citizen petition with the FDA asking that the agency delay approval of any … [Read more...] about Sandoz has discontinued its US generic Advair Diskus program
Evoke announces commercialization deal with Eversana for Gimoti nasal spray
Days after announcing that the FDA has accepted its NDA resubmission for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, Evoke Pharma said that the company has cancelled a previously announced commercialization deal with Novus Growth Partners and has signed a new 5-year deal with Eversana for commercialization and distribution of Gimoti … [Read more...] about Evoke announces commercialization deal with Eversana for Gimoti nasal spray
AstraZeneca announces plans for “next-generation inhaler” as part of “Ambition Zero Carbon” program
AstraZeneca has announced a commitment to launching a "next-generation" MDI with minimal global warming potential (GWP) propellants by 2025 as part of its $1 billion "Ambition Zero Carbon" program. The new program, which was announced at the World Economic Forum meeting in Davos, Switzerland, aims for zero carbon emissions by 2025 and a carbon negative value chain by … [Read more...] about AstraZeneca announces plans for “next-generation inhaler” as part of “Ambition Zero Carbon” program
Virpax to develop intranasal enkephalin formulation for the treatment of PTSD
Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company says that PES200 will be delivered via a cartridge-based, pressurized nasal delivery device, presumably the Naltos dry … [Read more...] about Virpax to develop intranasal enkephalin formulation for the treatment of PTSD
Altavant Sciences acquires Onspira Therapeutics
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101 for the treatment of bronchiolitis obliterans syndrome (BOS). According to Altavant, the deal included an upfront … [Read more...] about Altavant Sciences acquires Onspira Therapeutics
AI Therapeutics provides update on inhaled rapamycin
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the treatment of pulmonary arterial hypertension (PAH). The company said that LAM-001 has been granted Orphan Drug designation for LAM in Europe and … [Read more...] about AI Therapeutics provides update on inhaled rapamycin
Afrezza to be launched in Brazil
According to MannKind Corporation, Brazil's Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health Regulatory Agency (ANVISA) approved Afrezza for the treatment of diabetes in June 2019. In June 2017, MannKind announced that it … [Read more...] about Afrezza to be launched in Brazil
Impopharma acquired by Rubicon Research
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma's Concord, ON facility will become Rubicon's Nasal and Pulmonary Center of Excellence. Impopharma's services included testing and development of nasal sprays, MDIs, and DPIs. According to Rubicon, the company expects the … [Read more...] about Impopharma acquired by Rubicon Research